Clinical Trial Update: Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in combination with radiotherapy for metastatic triple-negative breast cancer has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer, Metastatic Triple Negative | Phase 2 | Status: COMPLETED | Results posted: 2019-10-04